An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ADC Therapeutics to Participate in February Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
ADC Therapeutics SA (NYSE: ADCT) announced that CEO Ameet Mallik will participate in two investor conferences in February. The first event is the Guggenheim Healthcare Talks – Oncology Day, scheduled for February 8, from 3:55 p.m. to 4:20 p.m. ET. The second is the SVB Securities Global Biopharma Conference, taking place virtually on February 14, from 8:00 a.m. to 8:30 a.m. ET. Webcasts for both events will be accessible on ADC Therapeutics’ investor website. ADC Therapeutics specializes in developing antibody drug conjugates, including ZYNLONTA, approved for treating certain types of lymphoma.
Positive
None.
Negative
None.
LAUSANNE, Switzerland--(BUSINESS WIRE)--
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in February.
Details of the events are as follows:
Guggenheim Healthcare Talks – Oncology Day, fireside chat on Wednesday, February 8th from 3:55 p.m. – 4:20 p.m. ET
SVB Securities Global Biopharma Conference (virtual), corporate update on Tuesday, February 14th from 8:00 a.m. – 8:30 a.m. ET
A live webcast of the fireside chat and presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company’s ability to continue to commercialize ZYNLONTA® in the United States and future revenue from the same; Swedish Orphan Biovitrum AB (Sobi®) ability to successfully commercialize ZYNLONTA® in the European Economic Area and market acceptance, adequate reimbursement coverage, and future revenue from the same; our strategic partners’, including Mitsubishi Tanabe Pharma Corporation and Overland Pharmaceuticals, ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions, and the timing and amount of future revenue and payments to us from such partnerships; the Company’s ability to market its products in compliance with applicable laws and regulations; the timing and results of the Company’s or its partners’ research projects or clinical trials including LOTIS 2, 5 and 9, ADCT 901, 601 and 212, the timing and outcome of regulatory submissions and actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates; projected revenue and expenses, the Company’s indebtedness including Healthcare Royalty Management and Oak Tree facilities and the restrictions imposed on the Company’s activities by such indebtedness, the ability to repay such indebtedness and the significant cash required to service such indebtedness; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
What investor conferences will ADC Therapeutics participate in February 2023?
ADC Therapeutics will participate in the Guggenheim Healthcare Talks on February 8 and the SVB Securities Global Biopharma Conference on February 14.
What is the schedule for ADC Therapeutics' investor conferences?
The Guggenheim Healthcare Talks will be on February 8, from 3:55 p.m. to 4:20 p.m. ET, and the SVB Securities Global Biopharma Conference will be on February 14, from 8:00 a.m. to 8:30 a.m. ET.
Where can I watch the ADC Therapeutics presentations?
The presentations can be streamed live via the Events & Presentations page on the ADC Therapeutics investor website.
What is ZYNLONTA, developed by ADC Therapeutics?
ZYNLONTA (loncastuximab tesirine-lpyl) is an FDA-approved treatment for relapsed or refractory diffuse large B-cell lymphoma.
What does ADC Therapeutics specialize in?
ADC Therapeutics focuses on developing next-generation antibody drug conjugates for cancer treatment.
